Article

Can Hidradenitis Suppurativa Predict Outcomes to Axial Spondyloarthritis?

A recent study suggests that the appearance of hidradenitis suppurativa may be another associated manifestation that can predict a more severe course of axial spondyloarthritis.

Hidradenitis Suppurativa (©Designer491_AdobeStock)

(©Designer491_AdobeStock)

The presence of extra-articular manifestations (EAMs) in axial spondyloarthritis (SpA) such as uveitis, psoriasis, and inflammatory bowel disease are frequently used to support the initial diagnosis and make treatment decisions. A recent study reported by Rondags et al. in Seminars in Arthritis and Rheumatism suggests that the appearance of hidradenitis suppurativa (HS) may be another associated manifestation that can predict a more severe course of SpA.

A higher prevalence of SpA has been reported in patients with HS, a chronic inflammatory skin disease producing disfiguring scarring and painful nodules at the terminal site of hair follicles, usually at the underarms, buttocks and groin regions. At the same time, heel enthesitis and dactylitis-both common features of SpA-have been associated with HS as well.

In the current study, investigators from the Netherlands examined the inverse correlation of HS in SpA using a screening questionnaire sent to all qualifying patients in the Groningen Leeuwarden Axial Spondyloarthritis (GLAS) cohort.

THE STUDY

A total of 449 questionnaires were included in the final analysis, representing 76% of the SpA cohort. The questionnaire asked for answers about current and past presence of HS symptoms, with pictures of the Hurley stages of HS and descriptions of lesions. Forty-seven of the 449 respondents were positive for a self-diagnosis of HS, and 3 had dermatologist confirmed diagnoses, for an overall prevalence rate of 9.1%.

The study found that SpA patients with HS were significantly more likely to be female and had greater self-reported SpA disease activity and worsened quality of life, compared to SpA patients without HS. The HS/SpA patients also showed trends toward being overweight and were more likely to be current or past smokers than those without HS.

TAKE-A-WAYS

The prevalence of HS in SpA patients in this study was 1.7 times that of the general population without SpA, supporting a bilateral correlation between the two diseases. Additionally, the authors suggest a potential shared pathology, supported by evidence from limited case control trials. They recommend that clinicians increase vigilance for HS symptoms in patients with SpA, particularly in female patients who are overweight and those who smoke. “The high prevalence and shared denominators in the pathogenesis and treatment may cautiously suggest that HS could be another EAM in (axial) SpA,” they concluded.

REFERENCE

Rondags A, van Straalen KR, Arends S, et al. High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. J Am Acad Dermatol 2019 Feb;80(2):551-554.e1. doi: 10.1016/j.jaad.2018.06.028. Epub 2018 Dec 14.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.